Analyst Price Targets — BNTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 11:03 am | — | Canaccord Genuity | $136.00 | $102.08 | TheFly | BioNTech price target lowered to $136 from $142 at Canaccord |
| August 5, 2026 11:04 am | — | Canaccord Genuity | $142.00 | $91.35 | TheFly | BioNTech price target raised to $142 from $138 at Canaccord |
| July 8, 2026 11:37 am | — | Morgan Stanley | $119.00 | $94.29 | TheFly | BioNTech price target lowered to $119 from $126 at Morgan Stanley |
| May 27, 2026 8:43 am | — | UBS | $135.00 | $92.25 | TheFly | BioNTech upgraded to Buy from Neutral at UBS |
| May 21, 2026 8:24 pm | — | Bernstein | $96.00 | $90.93 | TheFly | BioNTech initiated with a Market Perform at Bernstein |
| May 6, 2026 11:32 am | — | Canaccord Genuity | $158.00 | $95.50 | TheFly | BioNTech price target lowered to $158 from $171 at Canaccord |
| April 10, 2026 12:55 pm | Terence Flynn | Morgan Stanley | $126.00 | $93.38 | TheFly | BioNTech price target raised to $126 from $125 at Morgan Stanley |
| March 11, 2026 1:15 pm | Evan David Seigerman | BMO Capital | $128.00 | $90.52 | StreetInsider | BioNTech (BNTX) PT Lowered to $128 at BMO Capital |
| March 10, 2026 7:41 pm | Akash Tewari | Jefferies | $138.00 | $83.89 | StreetInsider | BioNTech (BNTX) PT Lowered to $138 at Jefferies |
| March 10, 2026 6:28 pm | Asthika Goonewardene | Truist Financial | $155.00 | $83.89 | StreetInsider | Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes |
Latest News for BNTX
BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
On CNBC's “Halftime Report Final Trades,” Kevin Simpson, founder and CEO of Capital Wealth Planning, picked Take-Two Interactive Software, Inc. (NASDAQ:TTWO).
BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. BNTX's next-gen anti-CTLA-4 gotistobart and PD-L1xVEGF-A bispecific antibody pumitamig have multiple pivotal trial catalysts, with key data readouts expected at WCLC 2026. COMIRNATY's XFG variant expansion provides near-term revenue, but COVID-19 vaccine sales face competitive and demand…
BioNTech (BNTX), the mRNA vaccine and oncology developer, pulled the plug on its Phase 2 colorectal-cancer trial Friday, with the stock priced at $103.39. Indep
BioNTech SE (NASDAQ:BNTX) shares are dropping Friday after the company announced it will terminate its Phase 2 clinical trial of autogene cevumeran in resected colorectal cancer. Here's what you should know.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.